Skip to main content
. 2020 Aug 28;73(9):e2995–e3001. doi: 10.1093/cid/ciaa1285

Table 1.

Demographic and Clinical Characteristics at Time of First Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR) Assay in Serum, by SARS-CoV-2 Serum PCR Status

Demographics PCR Negative
(n = 106)
PCR Positive
(n = 61)
Complete Data, No. (%)
Age, y 53 (45–67) 63 (52–74) 167 (100)
Sex, No. (%), female:male 36:70 (34:66) 23:38 (38:62) 167 (100)
Any comorbidity, No. (%) 74 (70) 48 (79) 167 (100)
Pulmonary disease, No. (%) 19 (18) 10 (16) 167 (100)
Any cardiovascular disease, No. (%) 15 (14) 18 (30) 167 (100)
Hypertension, No. (%) 35 (33) 30 (49) 167 (100)
Diabetes mellitus, No. (%) 21 (20) 13 (21) 167 (100)
Liver disease, No. (%) 3 (3) 0 (0) 167 (100)
Chronic renal disease, No. (%) 4 (4) 8 (13) 167 (100)
Malignancy, No. (%) 3 (3) 1 (2) 167 (100)
Immunosuppression, No. (%) 1 (1) 5 (8) 167 (100)
Body mass index, kg/m2 29 (25–32) 27 (25–31) 157 (94)
Days after symptom onset for sampling 10 (8–12) 9 (8–11) 165 (99)
Days after admission for sampling 1 (1–2) 1 (1–2) 167 (100)
Peak temperature, °C 38.1 (37.4–38.9) 39 (38.4–39.5) 167 (100)
Peak oxygen demand, L/min 0 (0–2) 3 (1–6) 167 (100)
C-reactive protein, mg/L 93 (49–168) 115 (74–240) 165 (99)
Procalcitonin, μg/L 0.17 (0.1–0.4) 0.32 (0.2–1.2) 107 (64)
Neutrophil, × 109/L 4.7 (3.4–6.6) 5.6 (3.6–8.0) 142 (85)
Lymphocyte, × 109/L 1.1 (0.8–1.4) 0.8 (0.6–1.3) 142 (85)
Neutrophil/lymphocyte ratio 4.6 (2.8–7.6) 6.4 (4.1–10.9) 142 (85)
Troponin T, ng/L 8 (5–10) 13 (8–24) 110 (66)
D-dimer, mg/L 0.8 (0.5–1.3) 1.0 (0.7–1.8) 105 (63)
Part of phase 1 or 2 convalescent plasma therapy study, No. (%) 4 (4) 28 (46) 167 (100)
Corticosteroid treatment, No. (%) 1 (1) 3 (5) 167 (100)

Data are presented as median (interquartile range) unless otherwise indicated.

Abbreviation: PCR, polymerase chain reaction.